Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 9, keine Gesamtzahl für „sections“
Suchtreffer
Begriffe & Kennungen
Taxotere · 4.8 · The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). Mi
Eintrag öffnenTaxotere · 4.8 · The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). Mi
Eintrag öffnenTaxotere · 4.8 · The development of severe peripheral neurotoxicity requires a reduction of dose (see sections 4.2 and 4.4). Mi
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Drug-laboratory test interactions (see sections 4.3 and 4.4)
Eintrag öffnenTenkasi (previously Orbactiv) · 4.5 · Drug-laboratory test interactions (see sections 4.3 and 4.4)
Eintrag öffnenTesavel · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see sections 4.4 a
Eintrag öffnenTeysuno · 4.8 · Patients with renal impairment (see sections 4.2, 4.3, 4.4, and 5.2)
Eintrag öffnenTeysuno · 4.8 · Patients with renal impairment (see sections 4.2, 4.3, 4.4, and 5.2)
Eintrag öffnenTransurethrale Resektion der Harnblase
Eintrag öffnenTransurethrale Resektion der Prostata
Eintrag öffnenTrecondi · 4.8 · Not known Blood lactate dehydrogenase (LDH) increased * See detailed sections below
Eintrag öffnenTrecondi · 4.8 · Not known γGT increased * See detailed sections below a Case reports (> 1) after treosulfan-based conditioning
Eintrag öffnenTrizivir · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. See sections 4.4
Eintrag öffnenUsymro · 4.5 · 6 undetectable (see sections 4.4 and 4.6). If there is a clear clinical benefit for the individual infant, adm
Eintrag öffnenVantavo (previously Alendronate sodium and colecalciferol, MSD) · 4.8 · *See sections 4.2 and 4.4 ‡This adverse reaction was identified through post-marketing surveillance. The frequ
Eintrag öffnenVelmetia · 4.3 · - hypersensitivity to the active substances or to any of the excipients listed in section 6.1 (see sections 4.
Eintrag öffnenVenclyxto · 4.3 · In all patients, concomitant use of preparations containing St. John’s wort (see sections 4.4 and 4.5).
Eintrag öffnenVivisektion
Eintrag öffnenVolibris · 4.3 · Women of child-bearing potential who are not using reliable contraception (see sections 4.4 and 4.6).
Eintrag öffnenVotubia · 4.5 · Potentiation of radiation treatment toxicity has been reported in patients receiving everolimus (see sections
Eintrag öffnen